AI Article Synopsis
- - Treatment for severe eczema in patients with primary immunodeficiencies is difficult due to a lack of specific guidelines.
- - Dupilumab, an IL-4Rα antagonist, effectively targets IL-4 and IL-13 and is approved for treating atopic dermatitis in children.
- - A specific case is highlighted where a patient with severe eczema related to Wiskott-Aldrich syndrome was successfully treated with dupilumab.
Article Abstract
Treatment of severe eczema in patients with primary immunodeficiencies can be particularly challenging as there are no guidelines with regards to these conditions. Dupilumab is an interleukin (IL)-4Rα antagonist that inhibits both IL-4 and IL-13 and is approved for the treatment of atopic dermatitis in pediatric patients. In this report, we describe a patient with a case of severe eczema in the context of Wiskott-Aldrich syndrome-related disorder, who was successfully treated with dupilumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.15397 | DOI Listing |
Publication Analysis
Top Keywords
severe eczema
12
wiskott-aldrich syndrome-related
8
syndrome-related disorder
8
disorder treated
8
treated dupilumab
8
eczema wiskott-aldrich
4
dupilumab treatment
4
treatment severe
4
eczema patients
4
patients primary
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!